Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients
Status:
Completed
Trial end date:
2017-06-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the pharmacokinetics of tiotropium +
olodaterol fixed-dose combination (FDC) (5 μg/ 5 μg) delivered by the RESPIMAT inhaler after
single dose and at steady state in Chinese patients with COPD.
The secondary objective is to assess the safety of tiotropium + olodaterol FDC (5 μg/ 5 μg)
delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Chinese patients with
COPD.